Genzyme-Isis cholesterol drug Kynamro wins FDA approval

01/29/2013 | Bloomberg Businessweek · Fox Business

Isis Pharmaceuticals and Sanofi unit Genzyme obtained FDA approval to market Kynamro, or mipomersen, as an add-on treatment to lipid-lowering drugs and diet for patients with homozygous familial hypercholesterolemia. Due to risks of liver problems, the once-weekly injectable drug will carry a boxed warning. The approval triggers the payment of a $25 million milestone fee from Genzyme to Isis.

View Full Article in:

Bloomberg Businessweek · Fox Business

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA